[1] World Health Organization. WHO position paper, meningococcal a conjugate vaccine: Updated guidance, February 2015 [J]. Vaccine, 2018, 36(24): 3421-3422.
[2] 丹尼斯·卡斯伯, 安东尼·福奇. 哈里森感染性疾病[M]. 3版.北京: 北京联合出版有限责任公司, 2017.
[3] MARTINELLI D, FORTUNATO F, PAATO R. Estimates of the burden of meningococcal disease in Italy: implications for prevention and control [J]. J Prev Med Hyg, 2015,56(3): E112.
[4] BANZHOFF A. Mu lticomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States [J]. Ther Adv Vaccines, 2017, 5(1): 3-14.
[5] ARRISON L H. Vaccines for prevention of group B meningococcal disease: not your father's Vaccines [J]. Vaccine, 2015, 33 (Suppl 4): D32-D38.
[6] JAFRI RZ, ALI A, MESSONNIER NE, et al. Global epidemiology of invasive meningococcal disease [J]. Population Health Metrics, 2013, 11(1): 17.
[7] PETERSON ME, LI Y, BITA A, et al. Meningococcal serogroups and surveillance: a systematic review and survey [J]. Journal of Global Health, 2019, 9(1): 010409.
[8] SI S, ZOMER E, FLETCHER S, et al. Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents [J]. Vaccine, 2019, 37(35): 5009-5015.
[9] HELEN C, MICHAEL E, NICK A, et al. Emergency meningococcal ACWY vaccination program for teenagers to control group W meningococcal disease, England, 2015-2016 [J]. Emerging Infectious Diseases, 2017, 23(7): 1184-1187.
[10] Crum-Cianflone N, Sullivan E. Meningococcal vaccinations [J]. Infect Dis Ther, 2016, 5(2): 89-112.
[11] Sridhar S, Greenwood B, Head C, et al. Global incidence of serogroup B invasive me ningococcal disease: a systematic review [J]. Lancet Infect Dis, 2015, 15(11): 1334-1346.
[12] Toneatto D, Pizza M, Masignani V, et al. Emerging experience with meningococcal serogroup B protein vaccines [J]. Expert Rev Vaccines, 2017, 16(5): 433-451.
[13] MacDougall D M, Langley J M, Li L, et al. Knowledge, attitudes, beliefs, and behaviors of university students, faculty, and staff during ameningococcal serogroup B outbreak vaccination program [J]. Vaccine, 2017, 35(18): 2520-2530.
[14] Fusco P C, Michon F, Tai J Y, et al. Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates [J]. J Infect Dis, 1997, 175(2): 364-372.
[15] MCNAMARA LA, SHUMATE AM, JOHNSEN P, et al. First Use of a Serogroup B meningococcal vaccine in the US in response to a university outbreak [J]. Pediatrics, 2015, 135(5): 798-804.
[16] FOLARANMI T, RUBIN L, MARTIN SW, et al. Use of serogroup B meningococcal vaccines in persons aged >/=10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015 [J]. Morbidity and Mortality Weekly Report, 2015, 64(22): 608-612.
[17] Soeters H M, Dinitz-Sklar J, Kulkarni P A, et al. Serogroup B meningococcal disease vaccine recommendations at a University, New Jersey, USA, 2016 [J]. Emerg Infect Dis, 2017, 23(5): 867-869.
[18] Parikh S R, Newbold L, Slater S, et al. Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007-08 and 2014-15: a qualitative and quantitative assessment [J]. Lancet Infect Dis, 2017, S1473-3099(17): 30170-30176.
[19] 朱兵清,高婉迎,徐丽,等. 中国B群脑膜炎奈瑟菌分子流行 病学特征分析[J]. 中华预防医学杂志,2019,53(2): 153-158. DOI:DOI:10.3760/cma.j.issn.0253⁃9624.2019.02.006.
[20] Guerin P J, Naess L M, Fogg C,et al. Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized noninferiority controlled trial in Uganda [J]. PLoS Negl Trop Dis, 2008, 2(12): e342.
[21] 柴志凯,李军,邵祝军,等.流行性脑脊髓膜炎监测与免疫预防专家研讨会会议纪要[J].中国预防医学杂志,2015,16(12):901-903
[22] 王华庆,安志杰,尹遵栋. 国家免疫规划七种针对传染病70年防控成就回顾[J].中国疫苗与免疫, 2019,25(4):359-367
[23] 国家卫生计生委. 国家免疫规划疫苗儿童免疫程序及说明 (2016 年版)[S]. 2016.
[24] 吴疆. 中国脑膜炎球菌疫苗预防接种专家共识[J]. 中国疫苗与免疫, 2019,25(1):96-101
[25] 衡宇, 查亚芳, 顾燕妮. 等，2018年美国儿童预防接种最新指南解读及其与我国现状比较[J]现代免疫学, 2018第38卷(4):350-353
[26] LUCIDARME J, LEKSHMI A, PARIKH S R, et al. Frequent capsule switching in 'ultravirulent' meningococci - are we ready for a serogroup B ST-11 complex outbreak? [J]. The Journal of Infection, 2017, 75(2): 95-103.
[27] JI XM, YAO PP, ZHANG LY, et al. Capsule switching of Neisseria meningitidis sequence type 7 serogroup A to serogroup X [J]. The Journal of infection, 2017, 75(6): 521-531.
[28] ZHU B, XU Z, DU P, et al. Sequence type 4821 clonal complex serogroup B Neisseria meningitidis in China, 1978-2013[J]. Emerging Infectious Diseases, 2015, 21(6): 925-932.
[29] 王萌,李艺星,李军宏,等. 2009-2010年中国流行性脑脊髓膜炎流行病学特征分析[J]. 疾病监测, 2012, 27(6):435.
[30] 冯蕾,熊萍,李漫时,等.山东省2006-2013年流行性脑脊髓膜炎流行特征及病原学监测[J]. 中华流行病学杂志,2014,35(12):1407.
